Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Graeme Parr"'
Autor:
Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Jeffrey R. Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Talha Munir
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical act
Externí odkaz:
https://doaj.org/article/62414b8a3edb44bbb17447d9b2f07ba8
Autor:
Keun-Wook Lee, Natasha Lukashchuk, Andrew Goldwin, Bienvenu Loembe, Graeme Parr, Irene Kang, Tobias Arkenau, R Roylance, Mario Campone, Claire Smith, Wassim Abida, Andrew J. Pierce, Duncan I. Jodrell, Alan Lau, Elhan Sanay, Sophie Postel-Vinay, Juanita Lopez, Sunyoung Rha, Emma Dean, Matthew G Krebs, Seock-Ah Im
Publikováno v:
Cancer Research. 81:PS11-18
Background: Alterations in BRCA1/2 are associated with ~9% of all BCs. Ola (a poly ADP-ribose polymerase inhibitor [PARPi]) is approved for treating pts with HER2-negative metastatic BC with germline BRCA mutation (gBRCAm), demonstrating an improveme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7adb672a1533851e637060bf557eb318
https://doi.org/10.1158/1538-7445.sabcs20-ps11-18
https://doi.org/10.1158/1538-7445.sabcs20-ps11-18
Autor:
Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Shringi Sharma, Graeme Parr, Veerendra Munugalavadla, Fanny Krantz, Helen Yang, Emma Dean, Richa Manwani, Peter Hillmen
Publikováno v:
Cancer Research. 82:CT532-CT532
Introduction: Patients (pts) with CLL who relapse on therapies targeting B-cell receptor signaling pathways have limited treatment options. Cerala, a selective oral ATR inhibitor, has shown synergistic preclinical activity with a Bruton tyrosine kina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d02a66644c239b886758955b4e6f8e5e
https://doi.org/10.1158/1538-7445.am2022-ct532
https://doi.org/10.1158/1538-7445.am2022-ct532
Autor:
Elkhan Sanay, Emma Dean, Natalia Lukashchuk, Andrew J. Pierce, Nisha Kurian, Graeme Parr, Bienvenu Loembe, Alan Lau, Wessel de Graaf, Rahul Aggarwal, Wassim Abida, Vidalba Rocher Ros
Publikováno v:
Journal of Clinical Oncology. 39:TPS189-TPS189
TPS189 Background: Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) are kinases that orchestrate cellular responses to DNA damage. ATM is primarily activated by DNA double strand breaks, and ATR is recruited to reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19676e50b595183f189f07cc39d1f0f0
https://doi.org/10.1200/jco.2021.39.6_suppl.tps189
https://doi.org/10.1200/jco.2021.39.6_suppl.tps189
Autor:
Bienvenu Loembe, Amit M. Oza, Mei Lin W. Ah-See, Alan Lau, Nisha Kurian, Andrew J. Pierce, Si-Houy Lao-Sirieix, Graeme Parr, Emma Dean
Publikováno v:
Journal of Clinical Oncology. 38:TPS6104-TPS6104
TPS6104 Background: Ovarian cancer is the leading cause of death from gynecological cancers in the USA, and the fifth most common cause of cancer death in women. Ola is a PARPi approved for first-line maintenance treatment of BRCA-mutated advanced ov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3488afaaae5d5771c717109b686e3434
https://doi.org/10.1200/jco.2020.38.15_suppl.tps6104
https://doi.org/10.1200/jco.2020.38.15_suppl.tps6104
Autor:
Graeme Parr, Michael Derks, Mary Phelan, Anne-Marie White, Lynn Turnbull, Nuria Bech, Markus Abt, Georgina Meneses-Lorente
Publikováno v:
The Journal of Clinical Pharmacology. 50:1188-1201
Dalcetrapib targets cholesteryl ester transfer protein and increases high-density lipoprotein cholesterol (HDL-C) levels. It is in clinical development for the prevention of cardiovascular events and will likely be used in combination with standard o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f13505e7a5e2d0e620bbb03bc3f6fe38
https://doi.org/10.1177/0091270009358709
https://doi.org/10.1177/0091270009358709
Autor:
Anne-Marie Young, Graeme Parr, Georgina Meneses-Lorente, Michael Derks, Markus Abt, Mary Phelan
Publikováno v:
Expert Opinion on Investigational Drugs. 19:1135-1145
Dalcetrapib, which targets cholesteryl ester transfer protein, is in clinical development for prevention of cardiovascular events and is likely to be used concomitantly with statins. Two studies investigated co-administration of dalcetrapib with ator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b51be2d86b686c93bdfe8338abd91ca
https://doi.org/10.1517/13543784.2010.509342
https://doi.org/10.1517/13543784.2010.509342